drugset / Trial / NCT02811185
Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose
Phase 4
Completed
1012 enrolled
University of Saskatchewan
Saskatoon Health Region · collabSylvia Fedoruk Canadian Centre for Nuclear Innovation · collab
Non-randomizedSingle-groupOpen-labelDiagnostic
Summary
This is a single-centre, open-label, non-randomized clinical trial designed to monitor the occurrence of adverse events associated with \[F-18\]-FDG Injection manufactured by the Fedoruk Centre. \[F-18\]-FDG Injection used in this clinical trial will be identical to commercial \[F-18\]-FDG that is already used at Royal University Hospital (RUH).
Timeline
- Start
- 2016-06
- Primary completion
- 2017-01
- Completion
- 2017-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F-18 FDG | Diagnostic / imaging agent | — | — |
Indications
No indication recorded.